Palvella Therapeutics (PVLA) Cash from Operations (2016 - 2024)
Historic Cash from Operations for Palvella Therapeutics (PVLA) over the last 12 years, with Q4 2024 value amounting to -$5.4 million.
- Palvella Therapeutics' Cash from Operations fell 12617.99% to -$5.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$10.8 million, marking a year-over-year increase of 2118.51%. This contributed to the annual value of -$10.8 million for FY2024, which is 2118.51% up from last year.
- Palvella Therapeutics' Cash from Operations amounted to -$5.4 million in Q4 2024, which was down 12617.99% from -$2.7 million recorded in Q3 2024.
- Over the past 5 years, Palvella Therapeutics' Cash from Operations peaked at $29.9 million during Q2 2021, and registered a low of -$22.6 million during Q1 2022.
- For the 5-year period, Palvella Therapeutics' Cash from Operations averaged around -$6.9 million, with its median value being -$10.4 million (2020).
- In the last 5 years, Palvella Therapeutics' Cash from Operations surged by 40584.99% in 2021 and then crashed by 15208.99% in 2022.
- Quarter analysis of 5 years shows Palvella Therapeutics' Cash from Operations stood at -$13.4 million in 2020, then grew by 18.43% to -$10.9 million in 2021, then fell by 18.17% to -$12.9 million in 2022, then skyrocketed by 258.1% to $20.4 million in 2023, then plummeted by 126.18% to -$5.4 million in 2024.
- Its Cash from Operations was -$5.4 million in Q4 2024, compared to -$2.7 million in Q3 2024 and -$1.6 million in Q2 2024.